Article

Iridex lasers receive FDA clearance

Iridex Corp. has received 510(k) clearance from the FDA for a family of laser systems (IQ 532, IQ 577, IQ 630-670, and IQ 810) and their associated delivery devices to deliver laser energy in three different modes (CW-Pulse, MicroPulse, and LongPulse).

Key Points

Mountain View, CA-Iridex Corp. has received 510(k) clearance from the FDA for a family of laser systems (IQ 532, IQ 577, IQ 630-670, and IQ 810) and their associated delivery devices to deliver laser energy in three different modes (CW-Pulse, MicroPulse, and LongPulse). In addition to use in the field of ophthalmology, the lasers are intended for use in the areas of otolaryngology and dermatology.

"The design concept of the IQ family enables us to provide different solid-state lasers on a common platform," said Theodore A. Boutacoff, Iridex president and chief executive officer. "This 510(k) covers green (532 nm), yellow (577 nm), red (630-670 nm), and infrared (810 nm) single-wavelength systems. We expect this common platform concept to facilitate the efficient development and timely introduction of related products."

The company will launch the laser delivering 577-nm yellow light first because it provides a wavelength not available in laser systems already on the market.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times)  ASCRS 2025: Joaquin De Rojas, MD, leverages machine learning model to predict arcuate outcomes
(Image credit: Ophthalmology Times) ASCRS 2025: AnnMarie Hipsley, DPT, PhD, presents VESA for biomechanical simulation of presbyopia progression
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
© 2025 MJH Life Sciences

All rights reserved.